ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

PEAR Pear Therapeutics Inc

0.0292
0.00 (0.00%)
27 Sep 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Pear Therapeutics Inc NASDAQ:PEAR NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.0292 0.03 0.0304 0 01:00:00

Pear Therapeutics to Participate in the 2023 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

02/02/2023 1:00pm

Business Wire


Pear Therapeutics (NASDAQ:PEAR)
Historical Stock Chart


From Sep 2022 to Sep 2024

Click Here for more Pear Therapeutics Charts.

Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the Company will participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which takes place February 14 - 16, 2023 in Snowbird, UT. Pear management will participate virtually in 1x1 meetings at the conference.

BTIG hosted events are intended for prospective and existing BTIG clients only. To request a meeting with Pear management, please contact your BTIG representative to express interest.

About Pear Therapeutics

Pear Therapeutics, Inc., which is traded on Nasdaq as PEAR, is the parent company of Pear Therapeutics (US), Inc. Pear is the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs). Pear aims to redefine care through the widespread use of clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear has the first end-to-end platform to discover, develop, and deliver PDTs to patients and a pipeline of products and product candidates across therapeutic areas, including the first three PDTs with disease treatment claims from the FDA. Pear’s product, reSET®, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from the FDA to treat disease. Pear’s second product, reSET-O®, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. Pear’s third product, Somryst® for the treatment of chronic insomnia, was the first PDT submitted through FDA’s traditional 510(k) pathway while simultaneously reviewed through FDA’s Software Precertification Pilot Program. For more information, visit Pear at www.peartherapeutics.com.

Media and Investors: Meara Murphy Senior Director, Corporate Communications meara.murphy@peartherapeutics.com

1 Year Pear Therapeutics Chart

1 Year Pear Therapeutics Chart

1 Month Pear Therapeutics Chart

1 Month Pear Therapeutics Chart

Your Recent History

Delayed Upgrade Clock